Skip to main content
Equibles
SKYE logo

SKYE · Skye Bioscience, Inc.

Track SKYE — free

Use SKYE with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about SKYE

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.42 -0.08 (-16.03%) At close · Aug 17
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“If adequate funds are not available to the Company when needed it will be required to curtail or perhaps cease operations which would, in turn, further raise substantial doubt about its ability to continue as a going concern. These conditions give rise to substantial doubt as to the Company's ability to continue as a going concern within one year after the date that these financial statements are issued.”
View the 10-Q filed Aug 14, 2026
Market Cap
$17.76M
Shares
35.42M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.50 Open$0.86 Day$0.47–0.88 52W close$0.47–4.75 Avg vol 30d350K Short int1.3M · 3.7% float · 12.6d Short vol54% Last earningsMar 10, 2026 DataSep 2023–Aug 2026 Filing10-Q · Aug 14

Raw chart and full-history price indicators begin at the captured split on Sep 8, 2023; bars on opposite sides are not compared.

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 14, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Strong Sell
      SellHoldBuy
      Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High
      Market backdrop VIX 14.3 · calm Equity put/call 0.52
      Technical
      price trend
      Strong Sell
      50 / 200-day cross No cross
      Price vs 200-day avg −42%
      below
      Price vs 50-day avg −24%
      below
      RSI (14) 34
      neutral
      MACD trend Negative
      52-week position 1%
      near low
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Very Weak
      1-month return −23%
      trailing
      6-month return −37%
      trailing
      YTD return −33%
      this year
      Relative strength −51%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $1 › 200d $1 — 200d above 50d
      Institutional flow Accumulating
      +10% holders QoQ · +8 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      3.72% of float · ▲ +24.9% MoM · 12.6 days cover
      Volume signal Reversal watch
      High volume on a down day — possible exhaustion
      Institution breadth Steady
      44 holders — mid 3-yr range
      Squeeze score 62
      elevated · 0–100
      Fundamentals
      Weak
      EPS growth −93%
      Y/Y
      Free cash flow $-43.1M
      Balance sheet $5.9M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 104%
      annualized · 1-yr
      Max drawdown −90%
      past year
      ATR 15.7%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Technicals

      trend & momentum for long-term holders Strong Sell
      4 · 3 · 0
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −42% Bearish
      Price vs 50-day avg
      −24% Bearish
      RSI (14)
      34 Neutral
      MACD trend
      Negative Bearish
      52-week position
      1% Bearish
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Mixed
      Trend (MA cross) No cross
      50d $1 › 200d $1 — 200d above 50d
      Institutional flow Accumulating
      +10% holders QoQ · +8 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      3.72% of float · ▲ +24.9% MoM · 12.6 days cover
      Volume signal Reversal watch
      High volume on a down day — possible exhaustion
      Institution breadth Steady
      44 holders — mid 3-yr range
      Price context
      position in its 52-week range
      Range low $0 Now $1 · 1% Range high $5
      vs 200-day avg -42% vs 50-day avg -24%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      SKYE
      Skye Bioscience, Inc.
      this stock
      		$17.76M -33.1% — — 3.7%
      ONC
      BeOne Medicines Ltd.
      		 $513.62B +14.4% +22179.2% 789.7 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $128.19B +11.6% +46.2% 29.5 1.6%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $82.72B +4.1% +20.8% 19.9 3.3%
      ARGX
      Argenx SE
      		 $52.94B +17.5% — — 2.1%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Reducing
      Holders
      44
      % held
      45.6%
      Net QoQ
      -78.7K sh
      Top holder
      5AM Venture Management, L…
      Held Float
      View
      Held by Funds
      Fund positions
      11
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      1.3M
      Days to cover
      12.6d
      Change
      +262.4K sh
      View
      Short Volume
      Short vol %
      54%
      As of
      Aug 17, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      39.6K
      Value
      $24.6K
      As of
      Jul 30, 2026
      View
      Off-Exchange
      Off-exchange %
      68.4%
      Week of
      Jul 13, 2026
      Off-exch Lit
      View
      Financials
      Financials
      Net income (FY)
      $-55.9M
      EPS diluted
      $-1.41
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 14, 2026
      This year
      14
      View
      Proposed Sales
      Value
      $126.1K
      Shares
      22.9K
      Filed
      Nov 15, 2024
      View
      Exempt Offerings
      Offering
      $40.0M
      Filed
      Mar 27, 2024
      View
      Earnings & Events
      Earnings Calls
      Last call
      Mar 10, 2026
      View

      Performance

      Raw-price comparisons begin at the captured split on Sep 8, 2023; windows that need an earlier baseline remain unavailable.

      5D 20D 120D MTD YTD
      SKYE -3.5% -22.7% -37.3% -11.8% -33.1%
      SPY +0.4% +4.5% +13.8% +3.9% +13.9%
      vs SPY -3.9% -27.2% -51.1% -15.7% -47.0%
      Key facts CIK 1516551 CUSIP 83086J200 13F (30d) 43 filings 43 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)